Assenagon Asset Management S.A. Boosts Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Assenagon Asset Management nearly doubled its Bristol Myers Squibb holdings in the second quarter, increasing its position by 95.6% to 124,569 shares valued at approximately $7.18 million. Institutional investors collectively own 76.41% of BMY.
• Analyst sentiment remains positive: BMY has a “Moderate Buy” consensus rating and an average price target of $66.06, while recent firms raised ratings, targets and earnings estimates.
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share and revenue of $12.97 billion, beating estimates, and announced a $2.52 annualized dividend yielding about 4%. The company also plans a $2.3 billion manufacturing campus in Houston.

Assenagon Asset Management S.A. boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 95.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 124,569 shares of the biopharmaceutical company's stock after buying an additional 60,886 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Bristol Myers Squibb were worth $7,178,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BMY. Clark Asset Management LLC lifted its position in Bristol Myers Squibb by 9.0% during the second quarter. Clark Asset Management LLC now owns 3,726 shares of the biopharmaceutical company's stock valued at $215,000 after purchasing an additional 309 shares in the last quarter. Bill Few Associates Inc. raised its stake in shares of Bristol Myers Squibb by 23.3% in the second quarter. Bill Few Associates Inc. now owns 11,876 shares of the biopharmaceutical company's stock worth $684,000 after buying an additional 2,245 shares during the period. Foster Group Inc. raised its stake in shares of Bristol Myers Squibb by 5.5% in the second quarter. Foster Group Inc. now owns 4,281 shares of the biopharmaceutical company's stock worth $247,000 after buying an additional 224 shares during the period. Balefire LLC lifted its position in shares of Bristol Myers Squibb by 2.0% during the 2nd quarter. Balefire LLC now owns 18,299 shares of the biopharmaceutical company's stock valued at $1,054,000 after buying an additional 364 shares in the last quarter. Finally, GK Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $313,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on BMY shares. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an "overweight" rating on the stock. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Guggenheim reiterated a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst earnings estimates increased: Erste Group Bank raised its FY2026 EPS forecast for BMY to $6.96 from $6.34, matching the broader consensus, and lifted its FY2027 estimate to $6.51 from $6.10. The revisions suggest improving confidence in the company’s earnings outlook. Bristol Myers Squibb earnings estimate revisions
• Positive Sentiment: $2.3 billion Houston manufacturing campus: BMY plans to build an approximately 600,000-square-foot advanced manufacturing and life sciences facility at Generation Park in Houston. The project is expected to create about 500 permanent jobs and roughly 2,000 construction jobs, expanding the company’s U.S. production capacity and supporting its previously announced $40 billion domestic investment commitment. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Neutral Sentiment: Broker sentiment remains favorable but not strongly bullish: BMY continues to carry an average “Moderate Buy” recommendation. Recent commentary highlights the company’s growth portfolio and pipeline, but also cautions that generic competition and the stock’s prior gains could limit near-term upside. Bristol Myers Squibb receives Moderate Buy recommendation
• Negative Sentiment: Merger speculation is unconfirmed: Reports that BMY held merger discussions with AstraZeneca helped send AZN sharply lower, but neither company confirmed the talks. The lack of confirmation and skepticism from Wall Street may weigh on BMY by raising questions about deal costs, integration risks and strategic priorities, even though a combination would create one of the world’s largest drugmakers. AstraZeneca versus Bristol Myers Squibb merger speculation

Bristol Myers Squibb Price Performance

BMY stock opened at $63.66 on Wednesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company's fifty day moving average price is $59.09 and its 200-day moving average price is $58.80. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.10. The company has a market capitalization of $130.05 billion, a PE ratio of 14.02, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.96 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source